Glucagon-like peptide 1 and appetite
- PMID: 23332584
- PMCID: PMC3594872
- DOI: 10.1016/j.tem.2012.11.008
Glucagon-like peptide 1 and appetite
Abstract
Glucagon-like peptide 1 (GLP-1) and GLP-1 analogs have received much recent attention due to the success of GLP-1 mimetics in treating type II diabetes mellitus (T2DM), but these compounds may also have the potential to treat obesity. The satiety effect of GLP-1 may involve both within-meal enteroenteric reflexes, and across-meal central signaling mechanisms, that mediate changes in appetite and promote satiety. Here, we review data supporting the role of both peripheral and central GLP-1 signaling in the control of gastrointestinal motility and food intake. Understanding the mechanisms underlying the appetite-suppressive effects of GLP-1 may help in developing targeted treatments for obesity.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
Effects of GLP-1 on appetite and weight.Rev Endocr Metab Disord. 2014 Sep;15(3):181-7. doi: 10.1007/s11154-014-9289-5. Rev Endocr Metab Disord. 2014. PMID: 24811133 Free PMC article. Review.
-
Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.Int J Obes (Lond). 2016 Nov;40(11):1699-1706. doi: 10.1038/ijo.2016.121. Epub 2016 Aug 30. Int J Obes (Lond). 2016. PMID: 27434221 Clinical Trial.
-
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.Diabetes Obes Metab. 2002 Sep;4(5):329-35. doi: 10.1046/j.1463-1326.2002.00219.x. Diabetes Obes Metab. 2002. PMID: 12190996 Clinical Trial.
-
Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms.Peptides. 2020 Sep;131:170342. doi: 10.1016/j.peptides.2020.170342. Epub 2020 Jun 6. Peptides. 2020. PMID: 32522585 Review.
-
Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial.Br J Nutr. 2016 Jul;116(2):360-74. doi: 10.1017/S0007114516001872. Epub 2016 May 20. Br J Nutr. 2016. PMID: 27198187 Free PMC article. Clinical Trial.
Cited by
-
Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life.Card Fail Rev. 2024 Sep 11;10:e10. doi: 10.15420/cfr.2024.05. eCollection 2024. Card Fail Rev. 2024. PMID: 39309521 Free PMC article. Review.
-
Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity.Sci Rep. 2024 Jul 29;14(1):17363. doi: 10.1038/s41598-024-68234-9. Sci Rep. 2024. PMID: 39075112 Free PMC article.
-
Identifying selection signatures for immune response and resilience to Aleutian disease in mink using genotype data.Front Genet. 2024 Jul 12;15:1370891. doi: 10.3389/fgene.2024.1370891. eCollection 2024. Front Genet. 2024. PMID: 39071778 Free PMC article.
-
Outer Membrane Vesicles Released from Garlic Exosome-like Nanoparticles (GaELNs) Train Gut Bacteria that Reverses Type 2 Diabetes via the Gut-Brain Axis.Small. 2024 May;20(20):e2308680. doi: 10.1002/smll.202308680. Epub 2024 Jan 15. Small. 2024. PMID: 38225709
-
Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists.ESC Heart Fail. 2024 Apr;11(2):649-661. doi: 10.1002/ehf2.14560. Epub 2023 Dec 13. ESC Heart Fail. 2024. PMID: 38093506 Free PMC article. Review.
References
-
- Mojsov S, et al. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem. 1986;261:11880–11889. - PubMed
-
- Orskov C, et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43:535–539. - PubMed
-
- Edholm T, et al. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol Motil. 22:1191–1200. e1315. - PubMed
-
- McIntyre RS, et al. The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res. 237C:164–171. - PubMed
-
- Drucker DJ, Rosen CF. Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia. 54:2741–2744. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources